Business
Cosmo Pharmaceuticals publishes Annual Report 2024
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - March 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) has published today its Annual Report for the fiscal year ending December 31, 2024. As already outlined in the unaudited 2024 Full-Year ...
About this update from Cosmo Pharmaceuticals Nv
[{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"Dublin, Ireland--(Newsfile Corp. - March 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) has published today its Annual Report for the fiscal year ending December 31, 2024. As already outlined in the unaudited 2024 Full-Year results on March 6, 2025, the reporting year was characterized by strong financial performance, exceptional revenue growth, significant strategic advancements, and a clear roadmap for future sustained corporate developments.","length":485,"tagName":"p"},{"type":"text","content":"The key highlights from Cosmo’s Annual Report 2024 include:","length":65,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Consolidated and audited financial results 2024","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"Detailed overview of the successes achieved in 2024","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"Statutory sections such as the Corporate Governance section and the Compensation Report","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"ESG topics","length":10,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":195,"olType":false},{"type":"text","content":"Based on the 2024 Full-Year results and as already announced, the Board of Directors of Cosmo Pharmaceuticals proposes a dividend distribution of €2.05 per share (2024: €2.00 per share) to the Ordinary Annual General Meeting of Shareholders, that will take place on May 30, 2025. The invitation to this AGM including all proposed resolutions will be available on the Company’s website under https://www.cosmopharma.com/investors/general-meeting as of April 29, 2025.","length":484,"tagName":"p"},{"type":"text","content":"Giovanni Di Napoli, CEO of Cosmo, commented: “We are pleased to present Cosmo’s full Annual Report 2024 to our stakeholders today. This comes after we disclosed the unaudited results for 2024 two weeks ago. We now look forward to further interacting with investors, analysts and media professionals at our upcoming Investor Day, which will take place in Zurich on July 1.”","length":390,"tagName":"p"},{"type":"text","content":"The Annual Report 2024 and the ESG Report 2024 of Cosmo Pharmaceuticals are availa...